Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07020260 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies

Study acronym: PACMAN
StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
PACMAN is a phase I/II single arm, open-label, multi-center study evaluating the safety of human CD19 CAR-T (huCAR19) produced locally using the Miltenyi Prodigy in children, adolescents and young adults with relapsed/refractory CD19+ hematological malignancies for whom no standard of care treatment is available.
Trial Details
NCT Number NCT07020260
Lead Sponsor Princess Maxima Center for Pediatric Oncology
Collaborators: Dutch Cancer Society, Miltenyi Biomedicine GmbH, University Medical Center Utrecht (UMCU)
Conditions
(from sponsor)		 Leukemia, Lymphoma
Related terms Burkitt Lymphoma, Leukemia, Lymphoma
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov